Theravance Biopharma (TBPH) Misses Q4 EPS by 32c

Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($2.02), $0.32 worse than the analyst estimate of ($1.70). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $2.01 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Citi maintains buy ratings on Argentina power firms amid sector shifts
• Pinduoduo (PDD) Tops Q2 EPS by 98c